AstraZeneca Signs Second Licence Agreement with Rigel for Preclinical Asthma Drug
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 7 (Table of Contents)
Published: 2 Jul-2012
DOI: 10.3833/pdr.v2012.i7.1762 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Rigel Pharmaceuticals has partnered with AstraZeneca for a second time for the development and commercialisation of its inhaled JAK (Janus kinase) inhibitor R256, which is in preclinical development for moderate-to-severe chronic asthma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS